Colombia Medical Device Registration: 27 INVIMA FAQs on Classification, GMP and Imports (2026)

With official fees starting at approximately COP 4 million, registrations valid for 10 years, and automatic issuance within 2 business days for Class I/IIa devices, Colombia can be one of the most cost-effective entry points in Latin America for Chinese device manufacturers. These 27 questions explain classification, registration pathways, fees, documentation, registration holding obligations, import clearance and post-market compliance in one guide.

Colombia is Latin America’s fourth-largest economy, with a population of approximately 52 million and a universal health coverage system known as the SGSSS. Industry estimates place its medical device market at approximately USD 1.5 billion, with annual growth of approximately 5%-6%, and around 80% of equipment has long been imported. Third-party analysis of INVIMA’s public registration database identified approximately 61,000 records associated with Chinese manufacturers among approximately 423,000 device registration records, representing 14.4% and making China the second-largest source country after the United States.

Colombia also has comparatively low official registration fees for Latin America, 10-year registration validity and an automatic registration pathway for Class I/IIa devices. For Chinese manufacturers that already hold CE or FDA evidence, this offers a market where existing evidence can be reused, costs remain manageable and timelines are relatively predictable.

The following 27 questions explain the full Colombia registration process. All key conclusions have been checked against official Colombian sources, including statutory provisions, examples of INVIMA resolutions, the 2026 official fee schedule and the original UDI resolution. A verification note appears in the disclaimer at the end.

1. Market and Regulatory Framework (Q1-Q5)

Q1. Is the Colombian medical device market worth entering?

Yes, and it can serve as one of the first Latin American markets for a Chinese manufacturer. There are four main reasons:

• Market fundamentals: Colombia has a population of approximately 52 million and the SGSSS universal health coverage system, with a two-tier structure of EPS insurers and IPS service providers. Industry estimates value the device market at approximately USD 1.5 billion, growing by approximately 5%-6% annually, including an IVD market of approximately USD 300 million.
• Import dependence: approximately 80% of medical equipment has long been imported, while domestic manufacturing capacity remains limited.
• Established Chinese presence: third-party analysis of approximately 423,000 device registration records in the INVIMA database identified approximately 61,000 records for Chinese manufacturers, or 14.4%, making China the second-largest source country. The supply chain and distribution channels have therefore already been validated.
• Regulatory cost: official fees are low, at approximately COP 4 million per product; registrations are valid for 10 years; and Class I/IIa devices receive automatic issuance. Total holding costs are therefore comparatively low among major Latin American markets.

Q2. Which authority regulates medical devices?

INVIMA, the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (National Institute for Food and Drug Surveillance), operates under Colombia’s Ministry of Health and Social Protection (MSPS). It oversees device registration, commercialisation permits and health surveillance. INVIMA is recognised by PAHO/WHO as a high-level regional regulatory authority and became an IMDRF affiliate member in September 2025. Electronic submissions are made through the SIRIS system at siris.invima.gov.co.

Q3. Which documents form the core regulatory framework?

Q4. How are products classified, and how does this relate to the EU MDR?

Colombia uses four risk classes: Class I (low), Class IIa (medium-low), Class IIb (medium-high) and Class III (high). There is no Class IV, unlike in Brazil and Argentina.

The classification criteria in Article 6 of Decreto 4725 share their origins with the EU MDR. Systems are assessed independently, software is classified with its host device, a multi-purpose product is classified according to its highest-risk purpose, and conflicting rules are resolved in favour of the highest class. Article 7 provides 18 classification rules in four groups: non-invasive devices, invasive devices, additional rules for active devices and special rules.

Practical point: the boundaries between Classes I/IIa and IIa/IIb are the most likely to produce disagreement, and reviewers do not always interpret them identically. Do not simply copy an FDA classification. Where the result is uncertain, seek a pre-submission classification consultation before filing to avoid months of rework.

Q5. Which rules apply to IVDs and custom-made devices?

• IVDs: Decreto 3770/2004 applies, with a separate three-class system comprising Classes I, II and III. Classes I/II use automatic registration, while Class III requires prior approval by INVIMA’s specialised committee, the Sala Especializada. A certificate of free sale is required for every class. Validity is 10 years for Classes I/II and 5 years for Class III.
• Custom-made devices (dispositivos sobre medida): Article 1 of Decreto 4725 expressly excludes them from its scope, and they are governed by other provisions.
• Equipment using controlled technologies, such as radiation or lasers: a commercialisation permit (permiso de comercializacion) is required regardless of class, including for repair spare parts.

2. Registration Pathways, Timelines and Fees (Q6-Q10)

Q6. What registration pathways are available?

Under Decreto 4725, devices that do not use controlled technologies have two principal pathways, while equipment using controlled technologies is treated separately:

• Automatic registration (registro sanitario automatico, Article 17): applies to Class I/IIa devices. Once the documents have been submitted and conformity confirmed, INVIMA immediately issues a registration number, allowing import and sale while retaining the right to conduct a subsequent review. If that review identifies deficiencies, INVIMA issues a correction request, and the registration may be cancelled if the holder refuses to cooperate. Automatic approval does not mean exemption from review.
• Standard registration (registro sanitario, Article 16): applies to Class IIb/III devices. INVIMA completes its technical review before approval, comprising documentary review and technical assessment, with Class III devices undergoing full review by the specialised committee. The product may not be sold before registration is granted.
• Commercialisation permit (Articles 23/24): specific to biomedical equipment using controlled technologies.

IVDs follow the same logic: Classes I/II use automatic registration, while Class III undergoes prior review.

Q7. What are the official review deadlines and practical timelines?

• Statutory deadlines: INVIMA publishes a deadline of 2 business days after submission for automatic registration. For standard registration, the decree sets a review deadline of 90 business days for INVIMA. Both periods exclude time spent on correction rounds.
• Practical timelines based on widespread industry experience: approximately 1-3 months for Class I/IIa after documents, certifications and translations are ready, and approximately 5-9 months for Class IIb/III. During review backlogs, Class III can take more than 12 months.
• Correction requests (requerimiento): the response period is generally 90 days, and failure to respond on time may result in cancellation of the registration application. Each correction round typically adds 1-3 months.

The conclusion is straightforward: plan against practical timelines, not statutory deadlines. Allowing a budget and schedule of 8-12 months for Class IIb/III devices is standard industry practice.

Q8. How much are the official fees?

Under the 2026 fee schedule in Resolucion 2025067543, issued on 2025-12-22 and amended by Resolucion 2026033499, official fees are denominated in UVB tax units and adjust with the UVB value:

At current exchange rates, this is approximately USD 900-1,400 per product, provided for reference only and subject to exchange-rate fluctuations. These amounts cover only official fees. They exclude local legal representative and importer service fees, official translations, apostilles, testing and other third-party costs. Total project costs usually exceed USD 2,000-3,000 per product. Trademark registration, if required, is separate and costs approximately COP 1.3-1.7 million per class.

Q9. What is the commercialisation permit for equipment using controlled technologies?

Biomedical equipment using controlled technologies, such as ionising radiation or lasers, requires a permiso de comercializacion before it can be manufactured, imported or sold in Colombia, regardless of risk class, because of its high risk and technical sensitivity. Spare parts used for repairs also require this permit. The official fee is 367.92 UVB, approximately COP 4.55 million.

Q10. Will the 2026 draft decree overturn the current system?

It will introduce changes, but it has not yet taken effect. Current submissions continue to be governed by Decreto 4725.

In January 2026, Colombia’s Ministry of Health published a draft Unified Decree on Medical Devices comprising approximately 16 chapters and 180 articles. It would replace both Decreto 4725/2005 and Decreto 3770/2004. Its principal proposed changes include:

• A three-tier authorisation model: health notification (notificacion sanitaria) for low/medium-risk products, health registration (registro sanitario) for high/very-high-risk products, and a commercialisation permit (permiso de comercializacion) for controlled technologies.
• Validity: the fixed 10-year term would change to indefinite validity linked to post-market performance, shifting from periodic renewal to continuing compliance.
• Quality system standard: ISO 13485 would be expressly established as the GMP standard for medical devices.
• Foreign reliance: a mechanism would recognise assessments by foreign regulators such as the FDA, EMA and ANVISA.
• Scope: IVDs and SaMD would be brought into the unified framework, and UDI requirements would move forward to the initial application.

Status: the draft was notified internationally to the WTO on 18 May 2026, and the international comment period closed on 17 July 2026. As of publication in October 2026, it had not been formally enacted. The draft proposes an 18-month transition period following enactment.

Recommended strategy: proceed under the current regulations while preparing the dossier to a reusable-evidence standard, including CE/FDA technical documentation, ISO 13485 and UDI data. These assets will remain useful under either the existing or proposed framework.

3. Local Partners and Submission Documents (Q11-Q18)

Q11. Why must a foreign manufacturer appoint a local legal representative?

A foreign manufacturer cannot file directly with INVIMA. It must appoint a Colombian legal representative (apoderado / representante legal), who submits the registration application, receives official INVIMA communications (oficio), responds to correction requests, and assumes local regulatory and post-market responsibilities. This is a mandatory requirement under Decreto 4725 and one of the most common reasons for INVIMA to reject an application.

Q12. What is the relationship between the registration holder (Titular) and the importer?

This is one of the biggest differences between the Colombian and EU systems and should be resolved before designing the distribution structure:

• Titular (registration holder): the entity named as holder on the registration certificate. Article 20 requires the certificate to state the holder’s name and address. In practice, the holder is almost always a Colombian entity, such as a local importer, agent or consultancy, or the manufacturer’s own Colombian subsidiary.
• Manufacturer: issues a power of attorney (POA), which must be apostilled and translated into Spanish, authorising the designated party to handle registration under Article 29.
• Importer: the importing entity named on the certificate. It carries out importation, storage and distribution and must hold a valid CCAA.

Examples of INVIMA registration resolutions show that a typical certificate identifies three roles: the Titular, such as a local company in Bogota; the Fabricante, meaning the foreign manufacturer; and the Importador, a local entity.

Commercial point: address four matters in the distribution agreement – registration ownership, access to the dossier, responsibility for safety reporting, and exit/transfer provisions. Agreeing these terms before signing is preferable to negotiating after a dispute arises.

Q13. What is CCAA, and what qualifications does an importer need?

CCAA, the Certificado de Capacidad de Almacenamiento y Acondicionamiento (Certificate of Storage and Conditioning Capacity), is an administrative authorisation issued by INVIMA to certify that a device importer meets sanitary conditions. It is governed by Resolucion 4002/2007 and covers facilities, storage conditions, hygiene, personnel training, document control and traceability. It is valid for 5 years and is subject to INVIMA inspection.

Key points:

• The importer must hold a valid CCAA, and both the registration and the CCAA must be valid for every import.
• The importer must appoint a technical director (director tecnico).
• When selecting an importer, manage the CCAA expiry date as a supply-chain expiry date.

Q14. How should the certificate of free sale (CFS) be prepared?

• Source: a certificate of free sale (Certificado de Venta Libre / CFS) issued by the competent authority in the country of origin.
• Alternative pathway: if the country of origin has no such system or the product is not sold there, evidence from a reference market recognised by INVIMA may be used: the United States, European Union, Canada, Japan or Australia.
• Authentication chain: an apostille and an official Spanish translation by a traductor oficial. Colombia is a party to the Apostille Convention. Since November 2023, China has also been able to issue apostilles directly, so consular legalisation is no longer required.
• Currency: CFS documents are subject to issuance-age requirements. An expired document is one of the most frequent reasons for correction requests, so obtain the CFS close to the submission date.

Q15. What quality system evidence is required? Is ISO 13485 sufficient, and is MDSAP accepted?

• ISO 13485:2016 is QMS evidence generally accepted by INVIMA. It is not mandatory for Class I/IIa devices but is strongly recommended. In practice it is essential for Class IIb/III devices, and the certificate scope must cover the manufacturer and products within the registration.
• BPM (Buenas Practicas de Manufactura), Colombia’s domestic GMP framework: INVIMA issues manufacturers a BPM compliance certificate (CCBPM), valid for 5 years. Before BPM certification is fully implemented, a technical and sanitary conditions opinion (Concepto Tecnico) serves as a transitional measure.
• MDSAP: Colombia is not an MDSAP member, and an MDSAP certificate cannot replace INVIMA’s product review. It can nevertheless provide indirect support during review as evidence of QMS maturity.
• In short: CE/FDA registration certificates do not create an automatic conversion route. INVIMA registration must still be completed.

Q16. What exactly must the technical dossier contain?

The core checklist under Article 18 on technical review documents and Article 19 on legal documents is as follows:

Technical section

• Application form signed by the technical director: product name, specifications, manufacturer, registration modality, service life, risk classification, intended use, international codes such as GMDN/ECRI, warnings and contraindications.
• Copies of quality system certificates, including CCAA, BPM or equivalent evidence such as ISO 13485.
• Product description: principal components, composition, specifications and operating principle.
• Technical studies of the design and finished product, and summaries of verification and validation, including test reports.
• Sterilisation method and disposal method, where applicable.
• Draft labels and instructions for use.
• For biomedical equipment: a statement regarding Spanish operating and maintenance manuals.
• For Class IIa/IIb/III devices: scientific information supporting safety, risk analysis, the solution demonstrating compliance with essential safety and performance requirements, and a list of applicable standards.
• For Class IIb/III devices: clinical-use study information.
• Certificate of free sale.

Legal section

The applicant’s name and evidence of legal existence and representation, power of attorney (POA), and proof of fee payment.

All documents must be in Spanish.

Q17. What clinical evidence is required?

Requirements are graduated by class:

• Class IIa: a technical rationale or literature review.
• Class IIb: more complete clinical data; copies of CE or FDA certification documents may be accepted.
• Class III: complete clinical evidence; CE technical documentation and FDA 510(k)/PMA data may be accepted.

The key point is that CE/FDA documentation is the most reliable accelerator. It can reduce correction rounds and shorten practical timelines, but it does not change the statutory review clock. For a Class III product without CE/FDA evidence, budget against the most conservative timeline.

Q18. What are the mandatory UDI requirements?

Resolucion 1405 de 2022 established the UDI-DI and semantic reporting system, which is now in its implementation period:

• Products registered on or after 8 February 2024 must obtain UDI-DI codes and complete semantic reporting before commercialisation, submitted through the INVIMA platform with payment of the applicable fee.
• Existing registrations granted earlier are transitioning in stages. The final transition deadline for Class IIa devices and Class I IVDs was 8 February 2026, which has passed.
• Recognised UDI issuing agencies are GS1, HIBCC, ICCBBA, IFA, Ali Health and ZIIOT. Chinese manufacturers commonly use GS1 or Ali Health.
• The semantic report must cover the device’s basic, regulatory and commercial attributes, including the GMDN code, manufacturer data, risk classification and commercial specifications.
• Non-compliance may result in suspension of commercialisation. Holders of existing registrations should verify their record status on the INVIMA platform as soon as possible.

4. After Registration: Validity, Changes and Post-Market Compliance (Q19-Q22)

Q19. How long is a registration valid, and how is it renewed?

• Validity: all Class I/IIa/IIb/III devices have a uniform validity of 10 years from the date of the administrative act granting registration. IVD validity is 10 years for Classes I/II and 5 years for Class III. Examples of INVIMA renewal resolutions expressly state that renewal is granted for 10 years.
• Renewal window: submit at least 3 months before expiry, or within 6 months before expiry for IVDs. If submitted on time, the certificate remains valid while renewal is reviewed.
• Late filing: an application outside the window is treated as a new application, with the review clock and fees starting again.
• Renewal difficulty: Class I/IIa renewals are usually approved automatically within several business days. Class IIb/III renewals require review and post-market verification.
• Example registration number format: INVIMA 2025DM-0002510-R2, where the R suffix indicates the number of renewals.

Q20. What adverse event reporting obligations apply?

Under the national Tecnovigilancia programme established by Resolucion 4816/2008, manufacturers and importers share responsibility for the following:

• Serious adverse events: report to INVIMA within 72 hours of becoming aware of the event.
• Periodic reports: submit periodic post-market reports quarterly even if there are no reportable events.
• Recalls: develop and execute a recall plan in accordance with INVIMA instructions and report progress.
• Implantable devices: complete a patient implant card (tarjeta de implante) for every patient under Article 40.
• Traceability records: retain distribution traceability records under Article 63.

Violations may lead to suspension or cancellation of registration, import restrictions, substantial sanitary fines under the Health Code, Ley 9/1979, product seizure and even an order to cease operations. The 72-hour deadline is a strict red line. Do not enter into a registration holding arrangement without local response capability.

Q21. How should changes to product information be handled?

Changes fall into two categories:

• Administrative changes, including a change of importer or holder and certain label or warning adjustments: use the modification procedure (modificacion). With complete documents, approval usually takes several business days. The official fee for a legal modification is approximately COP 826,000.
• Technical changes, including changes to specifications, materials or performance: use the technical modification procedure. The official fee is approximately COP 1.06 million.
• Changes affecting product safety or effectiveness, including major changes to design, chemical composition or intended use: a new registration is required.

The principle is to determine first whether the change affects safety and effectiveness, and then decide between a modification and a new registration.

Q22. Can a registration be transferred, and what are the pitfalls of changing importers?

Yes, but it is not inexpensive. Changing the registration holder requires a Cesion del Registro, a formal administrative transfer procedure that industry experience indicates takes approximately 3-6 months. The outgoing party must cooperate; without the original holder’s endorsement, the transfer cannot proceed.

This is the principal commercial risk of distributor-held registrations. Replacing a distributor means replacing the registration holder, not merely changing suppliers. If the original partner fails to cooperate, the registration can become blocked and the product’s compliant market status uncertain.

Practical advice: either include transfer provisions, cooperation obligations and contractual penalties in the agreement, or use a neutral registration holding structure from the outset so that the registration does not move whenever the distribution channel changes.

5. Imports, Customs Clearance and Special Scenarios (Q23-Q26)

Q23. How are products imported and cleared after registration?

Every shipment must complete two steps:

• VUCE filing: the importer applies through the Single Window for Foreign Trade (VUCE) for INVIMA sanitary clearance (visto bueno), selecting INVIMA code 01 in the filing field under the framework of Article 48 of Decreto 4725.
• DIAN customs clearance: DIAN handles the customs declaration and nationalisation of the goods under customs regulations.

The two steps are parallel requirements, and completing one does not mean the other has been completed. Other key points are:

• Import duties are approximately 5%-15%, depending on the HS code, and some free trade agreements may reduce them.
• Most medical devices are exempt from value-added tax (IVA), but some consumables may not qualify, so the specific tariff code must be checked.
• Both the registration and the importer’s CCAA must be valid at the time of filing.

Q24. Can products be imported without registration?

There is one statutory exception: the special import authorisation under Article 48. If a device is essential and irreplaceable for sustaining life or relieving suffering, and domestic supply is insufficient, INVIMA may authorise its import without registration. The import is declared through VUCE and requires a certificate of free sale issued by the competent authority in the country of origin, evidence of legal incorporation and representation, and a product quality certificate.

This is an emergency or exceptional mechanism, not a routine pathway and certainly not a grey area for selling first and regularising later.

Q25. How are exhibition samples and temporary imports handled?

• Short-term imports, such as exhibitions and demonstration equipment: up to 6 months, with a possible 3-month extension.
• Long-term imports of capital equipment: up to 5 years.
• Samples with no commercial value and donated equipment: use INVIMA’s separate authorisation channel through the Grupo de Autorizaciones y Licencias.

Q26. What is the process for conducting local clinical testing in Colombia?

The sequence is ethics approval first, regulatory review second and importation third:

• Submit an ethics application to an institutional ethics committee (IEC) registered with INVIMA, which usually takes 4-8 weeks.
• After ethics approval, submit the clinical trial application to INVIMA with the device technical documentation, GMP/ISO 13485 evidence, trial insurance and Spanish informed consent forms, among other documents.
• After approval, obtain temporary import authorisation for the trial devices.
• Initiate the sites and begin enrolment.

The full process takes approximately 120-280 days, depending on product class and document completeness. Documents must be in Spanish, and insurance is mandatory. Data generated in accordance with ICH-GCP / ISO 14155 may be accepted by the FDA for foreign submissions as bridging data under 21 CFR 812.28. The international value of Colombian clinical data is relatively high, a point that is often overlooked.

6. Market Implementation Strategy (Q27)

Q27. What market-entry roadmap should Chinese manufacturers follow for Colombia?

The following seven steps are arranged by priority:

• Classify first: assess each product under Colombian rules and seek pre-submission consultation for borderline products. One classification error can cause months of rework.
• Reuse evidence: prioritise products that already have CE/FDA evidence and prepare the dossier to Spanish-language standards. This is the most effective way to shorten practical timelines.
• Establish the local structure: appoint a legal representative and an importer with a valid CCAA, and define the Titular arrangement, whether self-held or neutral. Contracts must specify registration ownership and exit provisions.
• Register in batches: launch Class I/IIa products first to generate cash flow quickly, while preparing Class IIb/III applications in parallel on an 8-12-month schedule.
• Address UDI and labelling: include them in the launch pack. Products registered after February 2024 must complete UDI requirements before commercialisation.
• Maintain a compliance calendar: establish a 72-hour adverse event response mechanism, begin renewal preparation 6 months before expiry and submit quarterly periodic reports.
• Monitor the new decree: proceed under current regulations, but retain evidence to the standards of the proposed indefinite-holding and reliance framework so that the dossier remains useful under either system.

The key conclusions in this article were verified against official Colombian sources in October 2026, including Decreto 4725 de 2005 and its amendments. Official fee amounts, review timelines and transitional arrangements are subject to INVIMA’s current official publications. This article is provided for industry information only and does not constitute legal advice.